Abstract: A diode region includes: an n-type first semiconductor layer provided on a second-main-surface side in the semiconductor substrate; an n-type second semiconductor layer provided on the first semiconductor layer; a p-type third semiconductor layer provided closer to a first main surface of the semiconductor substrate than the second semiconductor layer; a first main electrode that applies a first potential to the diode; a second main electrode that applies a second potential to the diode; and a dummy active trench gate provided so as to extend from the first main surface of the semiconductor substrate and reach the second semiconductor layer. The dummy active trench gate includes the third semiconductor layer that is not applied with the first potential to be in a floating state on at least one of two side surfaces, and the dummy active trench gate is applied with a gate potential of the transistor.

Abstract: A semiconductor device includes: an insulating board; a circuit pattern disposed on the insulating board; a semiconductor chip connected to the circuit pattern; a case disposed on the insulating board to surround the circuit pattern and the semiconductor chip and not bonded to the insulating board; and a cured resin disposed in the case to seal the circuit pattern and the semiconductor chip.

Abstract: Provided is a technique for enhancing heat dissipation properties in dissipating heat generated in an electrode to a heatsink without impairing bonding properties between the electrode and a wire. In a semiconductor device, a portion of an electrode within an inner region defined by a case, at one surface, i.e., the lower surface with respect to a position in which a wire is connected, a resin portion is provided, the resin portion extending from an inner wall of the case to an upper-surface side of the heatsink. Additionally, in the portion of the electrode within the inner region defined by the case, at one surface, i.e., the lower surface with respect to a position in which the wire is not connected, a thermal conductor is provided, the thermal conductor having higher heat conductivity than the resin portion.

Abstract: A semiconductor device includes: an insulating board; a circuit pattern disposed on the insulating board; a semiconductor chip connected to the circuit pattern; a case disposed on the insulating board to surround the circuit pattern and the semiconductor chip and not bonded to the insulating board; and a cured resin disposed in the case to seal the circuit pattern and the semiconductor chip.

Abstract: Provided is a technique for enhancing heat dissipation properties in dissipating heat generated in an electrode to a heatsink without impairing bonding properties between the electrode and a wire. In a semiconductor device, a portion of an electrode within an inner region defined by a case, at one surface, i.e., the lower surface with respect to a position in which a wire is connected, a resin portion is provided, the resin portion extending from an inner wall of the case to an upper-surface side of the heatsink. Additionally, in the portion of the electrode within the inner region defined by the case, at one surface, i.e., the lower surface with respect to a position in which the wire is not connected, a thermal conductor is provided, the thermal conductor having higher heat conductivity than the resin portion.

Abstract: The present invention provides a pharmaceutical composition comprising at least one compound selected from the group consisting of (S)-isoproterenol, (S)-isoproterenol dipivalate, (S)—N-ethylnoradrenaline, (S)—N-n-Propylnoradrenaline, (S)—N-Butylnoradrenaline, (R, S)—N-tert-butylnoradrenaline, 1-(3, 4) dihydrooxylphenyl)-2-(isopropylamine)-1-(R, S)-butanol, (S)-1-(N-isopropyl)-3-methyldopamine and (R)-1-(N-isopropyl)-3-methyldopamine suitable. The pharmaceutical composition may be for topical application to ocular tissues.

Abstract: The present invention provides a method for inhibiting angiogenesis in a human subject in need of such inhibition. The method comprises administering to the human subject an anti-angiogenic effective amount of a physiologically tolerated salt thereof, or any mixture of the compounds of formula (I) a physiologically tolerated salt thereof, a prodrug thereof, a physiologically functional derivative thereof or any mixture thereof as an anti-angiogenic agent. The anti-angiogenic agent should have greater lipophilicity than (S)-noradrenaline.

Abstract: A catecholamine or related compound having (S)-configuration at ?-carbon, a physiologically tolerated salt thereof, a prodrug thereof, a physiologically functional derivative thereof or any mixture thereof and having a lipophilicity greater than (S)-noradrenaline has use as an anti-angiogenic agent. A catecholamine or related compound in which a ?-hydroxy group has been modified are also anti-angiogenic. The anti-angiogenic agent is preferably a compound of formula (I) or (II) a physiologically tolerated salt thereof, a prodrug thereof, a physiologically functional derivative thereof or any mixture thereof.

Abstract: The invention relates to a new “gene-switch” (cumate-inducible switch) for mammalian cells, having a mammalian promoter which has a TATA element and is linked to the coding sequence of CymR. This switch is as useful in the development of expression systems and cell-based assays for functional genomics as in the generation of viral vectors for gene therapy.

Abstract: The invention disclosed relates to the use of anti-glycation agents of formula (I), wherein X represents NR7, wherein R7 represents hydrogen atom or an acyl group derived from a linear, branched or cyclic C1-10 aliphatic acid or a C6-10 aromatic acid, R1 represents hydrogen atom, NH2, or a linear, branched or cyclic C1-10 alkyl which may be substituted with a C6-10 aromatic group, R2 represents hydrogen atom, a linear, branched or cyclic C1-10 alkyl, or COOH group, R?2 represents hydrogen atom or a linear, branched or cyclic C1-10 alkyl group, R3 represents hydrogen atom, ?O, OR8, SR8, or NR8R9, wherein R8 and R9 represent hydrogen atom, a linear, branched or cyclic C1-10 alkyl, or an acyl group derived from a linear or branched C1-10 aliphatic acid or a C6-10 aromatic acid, provided that R8 and R9 are not both an acyl group, R4 and R5 each independently represents OH, NH2, or SH, R6 represents hydrogen, F, Cl, Br, I, OR10, or SR10, wherein R10 represents hydrogen or an acyl group derived from a linear o

Abstract: The invention relates to a new “gene-switch” (cumate-inducible switch) for mammalian cells. This switch is as useful in the development of expression systems and cell-based assays for functional genomics as in the generation of viral vectors for gene therapy.

Abstract: The invention relates to a new “gene-switch” (cumate-inducible switch) for mammalian cells. This switch is as useful in the development of expression systems and cell-based assays for functional genomics as in the generation of viral vectors for gene therapy.

Abstract: A catecholamine or related compound of formula (I) having (S)-configuration at ?-carbon and having a lipophilicity greater than (S)-noradrenalme, a physiologically tolerated salt thereof, a prodrug thereof, a physiologically functional derivative thereof or any mixture thereof is useful as an anti-angiogemc agent A catecholamine or related compound of formula (II) in which a ?-hydroxy group has been modified is also anti-angiogemc

Abstract: The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.

Abstract: A new method of designing and generating compounds having an increased probability of being drugs, drug candidates, or biologically active compounds, in particular having a therapeutic utility, is disclosed. The method consists of identifying a group of bioactive compounds, preferably of diverse therapeutic uses or biological activities and built on a common building block. In this group of compounds, side chains modifying the building block are identified and used to generate a second set of compounds according to the proposed methods of hybridization”, “single substitution” or “incorporation of frequently used side chains”. If the compounds in the second set built on the same building block contain an unusually large number of drugs, preferably with diverse therapeutic uses or biological activities, they constitute a “hot spot”.

Abstract: A process for preparing an active animal cell-growth-enhancing fraction of a hydrolysate of plant tissue, animal tissue or microorganism ultrafiltrate material, especially a fraction of a yeastolate ultrafiltrate, comprising forming a precipitate from said fraction with a water-soluble solvent is disclosed. Such solvents as alkanols, alkyl sulfoxides, ketones or alkyl nitriles, especially lower (C1-C5) alkanols, particularly ethanol, can be used. The invention also relates to an active animal cell-growth-enhancing fraction of a hydrolysate of plant tissue, animal tissue or microorganism ultrafiltrate material, especially a fraction of a yeastolate ultrafiltrate, substantially free of aromatic and methyl group bearing compounds which has improved cell-growth-enhancing properties.

Abstract: The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.

Abstract: The invention relates to a new “gene-switch” (cumate-inducible switch) for mammalian cells. This switch is as useful in the development of expression systems and cell-based assays for functional genomics as in the generation of viral vectors for gene therapy.

Abstract: A spool valve includes a sleeve and a spool. The sleeve has a first communicating hole opening into the cylinder bore and a second communicating hole opening into the cylinder bore and separated from the first communicating hole in the axial direction of the cylinder bore. The spool is fluidtightly accommodated in the cylinder bore to slide and has one end portion which opens and closes the first communicating hole upon sliding operation thereof and the another end portion which opens and closes the second communicating hole upon sliding operation thereof. At least one of the end portions has an end surface extending from the outer circumference approximately at a right angle to the spool axis and an inclined surface which progressively decreases a diameter of the spool from the end surface.

Abstract: A brake control device for a vehicle includes a master cylinder, a wheel cylinder, a brake pedal behavior simulator, a normally-open type electromagnetic valve, a normally-closed type electromagnetic valve, and a brake pressure control device. The brake pressure control device includes a pump, a reservoir, and two electromagnetic valves to increase and decrease wheel cylinder hydraulic pressure. When the brake pressure control device is normally operated, a hydraulic pressure in the wheel cylinder is controlled by the brake pressure control device. On the other hand, when the brake pressure control device malfunctions or is abnormally operating, the wheel cylinder hydraulic pressure is controlled by hydraulic pressure generated from the master cylinder. At least the normally-closed type electromagnetic valve is opened when the brake pedal is in the non-operational state.